RGCC International

06/11/2025

In a recent study, Statistician George Beis and our Director, Dr. Ioannis Papasotiriou, explored how different statistical tests perform when the proportional hazards (PH) assumption doesn’t hold in immuno-oncology trials.

Their findings show that while methods like weighted log-rank (GW), MK-S, and NY1/NY2 tests can better detect early or delayed treatment effects, no single test fits all scenarios. The authors recommend using a combination of robust, data-driven approaches to ensure accuracy and transparency in survival analyses.

📊 You can find all our published studies here:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

03/11/2025

Join us this as we shine a light on men’s health. From prostate and testicular cancer to mental health, men’s wellbeing matters.

At , we’re committed to transforming cancer care through precision diagnostics with a special focus on early detection that saves lives.

Let’s continue the conversation this Movember and support research that truly changes lives. Learn more about Movember here: https://ch.movember.com/en/?home

29/10/2025

🎥 Hear it from the experts!
Oncologists and healthcare professionals share why they trust RGCC testing to deliver accurate insights and guide personalized treatment for their patients.

📚 Explore our diagnostic tests and their clinical applications: rgcc-international.com

23/10/2025

At , we believe early detection and personalized testing can change the course of someone’s health journey.

B.T.’s story is a powerful reminder of how proactive choices and precision can lead to life-saving insights.

🌱 Explore more patient experiences: rgcc-international.com/testimonials/

20/10/2025

Through tailored tests, we aim to empower people facing cancer with tailored insights that can change the course of their journey. The aim of our cancer blood tests is to detect, analyze, and examine cells early at every stage of the disease.

Our minimally invasive liquid biopsy tests offer promising opportunities for early cancer detection and treatment. In this process, the focus is always on providing clinicians and patients with a clinical basis on which they can make well-founded and personalized decisions for individual cancer treatment.

Learn more > rgcc-international.com/tests/

15/10/2025

Watch as surgical oncologists Dr. Sonar Soni Panigoro and Dr. Walta Guatama share how RGCC’s Liquid Biopsy tests, including Oncotrace, are redefining how oncologists monitor cancer, offering patients a less invasive alternative to traditional biopsies.

09/10/2025

The biology of a cancerous tumor works similarly to skin or hair. Just like the body sheds hair and skin cells, the tumor sheds cells throughout its lifespan. These cells are called circulating tumor cells (CTCs), and they can be detected in the bloodstream. Therefore, when a blood sample is analyzed for diagnosis, the test will measure the presence of CTCs.

At , we use liquid biopsies to measure the CTC count. A liquid biopsy is a non-invasive way to measure cancer in the body by measuring the number of CTCs in the bloodstream.

The detection and monitoring of markers circulating in the blood are useful for the prognosis and prediction of a patient’s response to therapy.

Explore our full range of CTC tests for cancer screening and monitoring: https://rgcc-international.com/tests/

06/10/2025

Our team presented the poster: “Cell fusion model to investigate a potential origin of circulating cells.”

The study explores the cell fusion process, the merging of the membranes of two or more cells into one hybrid cell, which is associated with cancer initiation, progression, and metastasis. It particularly focuses on the fusion of and immune cells, which can create hybrid cells with unique properties, including drug resistance, immune evasion, and cancer progression. Therefore, the project aimed to establish an in vitro cell fusion model to investigate this important biological process.

📄 Explore the full poster and our published research: rgcc-international.com/published-articles/

📸 See highlights from the event below.

01/10/2025

🎗️ October is Breast Cancer Awareness Month 🎗️

Breast remains one of the most common cancers among women worldwide, but advances in early detection and targeted, personalized treatments are steadily improving outcomes.

At , we are committed to supporting both patients and practitioners with innovative approaches that go beyond conventional care. Personalized medicine offers the possibility of treatments precisely tailored to each individual, reducing strain while improving effectiveness.

💬 In honor of , we’re sharing both patient and practitioner testimonials that highlight the real impact of early detection and precision care. Read more testimonials via rgcc-international.com/testimonials/

29/09/2025

Our analytical laboratory in Switzerland is equipped with a state-of-the-art 600 MHz Bruker Avance III HD system with a BBFO probe. This setup allows us to perform high-sensitivity nuclear magnetic resonance testing on a wide array of nuclei, utilizing advanced decoupling capabilities.

Visit our website to see examples of the reports we provide, including:
• 1D Experiments
• 2D Experiments
• Quantitative NMR ( )
👉 rgcc-international.com/nmr/

25/09/2025

Relive the highlights from the International Gathering 2025! From 12–14 September in Zurich, we brought together 130+ participants from 34 countries to share breakthroughs in diagnostics, autologous treatments, and collaborative research.

A heartfelt thank you to our speakers, collaborators, and participants for making this year’s Gathering such a success.

🎥 This recap video captures the energy, innovation, and global spirit that defined three inspiring days of science and collaboration. Watch it here:

17/09/2025

We're proud to announce the successful conclusion of the International Gathering 2025, held from 12–14 September 2025 in Zurich.

This year’s Gathering welcomed over 130 participants from 34 countries, making it Europe’s largest and most dynamic meeting of RGCC scientists, clinicians, and collaborators. Over the course of three inspiring days, we explored cutting-edge advancements in diagnostics and autologous treatments, shared clinical insights, and strengthened global collaboration in the fight against cancer.

We are deeply grateful to everyone who contributed to the success of this event. Together, we continue moving closer to a future where science and innovation redefine possibilities in cancer care.

📸 Explore some highlights here.